Vivos Therapeutics (VVOS) is trading up at $0.15 (+1.52%), as of the latest quote. It operates in the Health Care sector.
| FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | $11.4M | $13.1M | $16.9M | $16.0M | $13.8M | $15.0M | $17.4M |
| Growth (year over year) | — | +14.7% | +29.2% | −5.1% | −13.9% | +8.9% | +16.0% |
| Gross profit | $8.66M | $10.4M | $12.6M | $10.0M | $8.27M | $9.02M | $10.5M |
| Gross margin | 76.0% | 79.7% | 74.6% | 62.5% | 59.9% | 60.0% | 60.4% |
| Operating income | −$10.6M | −$12.0M | −$20.4M | −$25.0M | −$17.3M | −$11.2M | −$19.9M |
| Operating margin | −92.8% | −92.1% | −120.7% | −156.2% | −125.3% | −74.3% | −114.1% |
| Net income | −$10.8M | −$12.1M | −$20.3M | −$23.8M | −$13.6M | −$11.1M | −$21.2M |
| Net margin | −94.4% | −92.3% | −120.2% | −148.8% | −98.4% | −74.1% | −121.4% |
| EPS (diluted) | −$593.75 | −$875.00 | −$600.00 | −$25.90 | −$11.14 | −$2.22 | −$2.07 |
| Balance sheet | |||||||
| Cash and equivalents | $469.4K | $18.2M | $24.0M | $3.52M | $1.64M | $6.26M | $2.03M |
| Total assets | $7.55M | $25.3M | $33.7M | $13.7M | $10.7M | $15.3M | $25.2M |
| Total liabilities | $9.18M | $8.41M | $8.15M | $8.92M | $10.3M | $7.33M | $26.7M |
| Long-term debt | $3.71M | $423.0K | $1.26M | — | $1.20M | $1.20M | $469.0K |
| Shareholders' equity | −$2.94M | $16.9M | $25.5M | $4.80M | $411.0K | $7.95M | −$1.49M |
| Cash flow | |||||||
| Operating cash flow | −$5.34M | −$5.68M | −$15.7M | −$19.6M | −$11.9M | −$12.7M | −$15.3M |
| Capital expenditure | $175.6K | $120.0K | $2.40M | $924.0K | $803.0K | $568.0K | $2.34M |
| Free cash flow | −$5.52M | −$5.80M | −$18.1M | −$20.5M | −$12.7M | −$13.3M | −$17.6M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $3.86M | $3.70M | $3.02M | $3.82M | $6.78M | $3.82M | $5.14M | $5.15M |
| Growth (year over year) | +16.9% | +13.9% | −11.8% | −5.8% | +75.7% | +3.4% | +70.5% | +34.9% |
| Gross profit | $2.33M | $2.10M | $1.51M | $2.11M | $3.94M | $2.99M | $3.06M | $2.95M |
| Gross margin | 60.5% | 56.7% | 50.0% | 55.2% | 58.0% | 78.1% | 59.5% | 57.3% |
| Operating income | −$2.65M | −$2.81M | −$3.92M | −$4.87M | −$4.73M | −$6.38M | −$6.62M | −$4.83M |
| Operating margin | −68.5% | −75.9% | −129.9% | −127.4% | −69.8% | −166.8% | −128.7% | −93.6% |
| Net income | −$2.62M | −$2.83M | −$3.86M | −$5.01M | −$5.40M | −$6.89M | −$7.68M | −$5.48M |
| Net margin | −67.8% | −76.4% | −128.1% | −131.2% | −79.6% | −180.3% | −149.4% | −106.4% |
| EPS (diluted) | −$0.40 | $0.41 | −$0.45 | −$0.55 | −$0.49 | −$0.58 | −$0.52 | −$0.31 |
| Balance sheet | ||||||||
| Cash and equivalents | $6.31M | $6.26M | $2.34M | $4.40M | $3.09M | $2.03M | $2.11M | $1.77M |
| Total assets | $15.3M | $15.3M | $11.3M | $26.0M | $25.6M | $25.2M | $25.0M | $24.1M |
| Total liabilities | $7.68M | $7.33M | $6.88M | $21.4M | $23.1M | $26.7M | $26.3M | $28.1M |
| Long-term debt | $1.20M | $1.20M | — | $7.76M | $8.38M | $469.0K | $418.0K | $366.0K |
| Shareholders' equity | $7.67M | $7.95M | $4.41M | $4.58M | $2.53M | −$1.49M | −$1.14M | −$3.81M |
| Cash flow | ||||||||
| Operating cash flow | −$4.19M | −$2.94M | −$3.80M | −$3.49M | −$4.16M | −$3.81M | −$6.01M | −$3.15M |
| Capital expenditure | $192.0K | $165.0K | $122.0K | $771.0K | −$83.0K | $1.53M | $18.0K | $416.0K |
| Free cash flow | −$4.38M | −$3.10M | −$3.92M | −$4.26M | −$4.08M | −$5.34M | −$6.03M | −$3.56M |
From Vivos Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Vivos Therapeutics in our feed yet.